[HTML][HTML] Evolving perceptions, utilization, and real-world implementation experiences of oncology monoclonal antibody biosimilars in the USA: perspectives from both …
J Yang, K Blinzler, J Lankin, S Vijayakumar… - BioDrugs - Springer
Background The adoption of oncology biosimilars has been slow in the USA, which may be
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
[HTML][HTML] Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from …
J Yang, K Blinzler, J Lankin, S Vijayakumar… - Biodrugs, 2022 - ncbi.nlm.nih.gov
Background The adoption of oncology biosimilars has been slow in the USA, which may be
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
Evolving Perceptions, Utilization, and Real‑World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both …
J Yang, K Blinzler, J Lankin, S Vijayakumar… - …, 2022 - search.proquest.com
Background The adoption of oncology biosimilars has been slow in the USA, which may be
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both …
J Yang, K Blinzler, J Lankin… - … and gene therapy, 2022 - pubmed.ncbi.nlm.nih.gov
Background The adoption of oncology biosimilars has been slow in the USA, which may be
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both …
J Yang, K Blinzler, J Lankin, S Vijayakumar… - … and Gene Therapy, 2021 - europepmc.org
Background The adoption of oncology biosimilars has been slow in the USA, which may be
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
[PDF][PDF] Evolving Perceptions, Utilization, and Real‑World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from …
J Yang, K Blinzler, J Lankin, S Vijayakumar… - 2021 - academia.edu
Background The adoption of oncology biosimilars has been slow in the USA, which may be
attributed in part to stakeholder perceptions and lack of operational guidance that supports …
attributed in part to stakeholder perceptions and lack of operational guidance that supports …